Stay updated on Nivolumab & Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab & Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab & Ipilimumab in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing Revision: v3.3.3.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedA centralized 'Locations' section was added listing Florida, Indiana, Massachusetts, Pennsylvania, Tennessee, and Virginia, replacing the previous separate location subsections. The footer link 'HHS Vulnerability Disclosure' was removed and the page revision updated to v3.3.3.SummaryDifference0.7%

- Check59 days agoChange DetectedPubMed publication text updated to reflect auto-fill from PubMed and the revision tag updated to v3.3.2. The previous, more detailed PubMed note and revision v3.2.0 were removed.SummaryDifference0.1%

- Check66 days agoChange DetectedDeleted a general funding/operating-status notice; no study content, eligibility criteria, or results were affected.SummaryDifference0.4%

- Check80 days agoChange DetectedThe update appears to be a visual/layout refresh without any changes to the study details like the title, condition, locations, enrollment, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check109 days agoChange DetectedUpdated the page to v3.2.0 with a new government-funding operating-status notice; removed the old v3.1.0 reference.SummaryDifference4%

Stay in the know with updates to Nivolumab & Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab & Ipilimumab in Melanoma Clinical Trial page.